After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.

Original title: “After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral”

While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.

Original title: “Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+”

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar control and weight reduction—albeit with a few extra discontinuations as compared to its rival.

Original title: “Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front”

/PRNewswire/ -- Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an... Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide. The partnership will ensure sustained commercial supply for FOP therapy and broaden capabilities to handle multiple highly potent compounds at commercial scale, addressing critical needs in rare disease treatment. Marlene Leuenberger, VP and General Manager, Quotient Sciences, Philadelphia commented: "This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences' unwavering commitment to supporting patients with ultra-rare diseases.

Original title: “Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment”

The rejection of Atara Biotherapeutics’ Ebvallo in January was a “complete reversal” of the conesensus FDA reviewers had come to, according to a former agency employee, who said manufacturing problems were the only approvability barrier for the drug.

Original title: “Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection”

Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business.

Original title: “Sarepta CEO Doug Ingram to retire, with company at a crossroads”

Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics’ liver-directed gene editor.

Original title: “Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy”

Contract work opportunities have grown year over year, and recent reports show more people are in this type of role, according to BioSpace data. Three biopharma professionals share why they’ve become contractors and discuss the pros and cons.

Original title: “The Right Fit: Contract Work Finds Increasing Favor Among Employers, Professionals”

Looking for a biopharma job in San Francisco or South San Francisco? Check out the BioSpace list of 10 companies hiring life sciences professionals like you.

Original title: “10 Companies Hiring in San Francisco and South San Francisco”

Alternatives to opioids are desperately needed to better treat moderate to severe acute pain, but to date, we’ve seen few novel analgesics hit the market.

Original title: “New Painkillers Critical To Fight Opioid Epidemic, Broader Pain Crisis”

One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug.

Original title: “Alkermes’ Richard Pops to step down after three-decade run as CEO”

The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.

Original title: “Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility”

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is throwing more money into the obesity space, striking a deal with Vivtex to advance novel weight loss pills.

Original title: “Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B”

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.

Original title: “GSK to acquire 35Pharma in $950M deal for cardiovascular drug”

Solstice Oncology will gain an exclusive worldwide license to Harbour BioMed’s porustobrt, an anti-CTLA-4 antibody currently being studied for melanoma, colorectal cancer and other malignancies in China.

Original title: “Harbour Cofounds Cancer Startup, Hands Off Clinical-Stage Antibody”

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines.

Original title: “With Vivtex deal, Novo gains a chance at better oral obesity drugs”

Slate Medicines will move forward with a migraine drug from a Chinese biotech, while Alveus Therapeutics will advance a dual GLP-1/GIPR fusion protein for weight loss.

Original title: “Slate, Alveus Raise Hefty Series A Hauls for Migraine, Obesity Drugs”

The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes.

Original title: “BreezeBio banks $60M to make more precise genetic medicines”

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion.

Original title: “Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval”